Poster Session B

Poster Session B
Saturday, February 26
7:30 p.m.-10:00 p.m.

In alphabetical order, not board assignment order

• 17-hydroxy-PX-866, the primary metabolite of PX-866, an irreversible, pan-isoform inhibitor of phosphatidylinositol-3 (PI3) kinase, has increased activity in biochemical and cellular assays. Kevin M. Klucher, Alex Vo, Christina Walker, Rob Rosler, Janelle Taylor, Jeff Millard, Scott Peterson. Oncothyreon Inc., Seattle, WA.
• A mouse model of basaloid breast tumors with a basal-type chemoresistant cancer stem cell. Soyoung Kim, Caroline Alexander. University of Wisconsin-Madison, Madison, WI.
• A novel series of tetrasubstituted purines potently inhibit mTOR and PI3K, exhibit striking selectivity and demonstrate good pathway inhibition in vivo. Meredith Williams¹, Stefan Hart¹, Zahid Bonday², Kee Chuan Goh¹, Veronica Diermayr¹, Yung Kiang Loh¹, Amalini Jesuthasan¹, Yong Cheng Tan¹, Bee Kheng Ng¹, Khalid Pasha Mohammed¹, Kantharaj Ethirajulu¹, Jeanette Wood¹, Harish Nagaraj¹, Brian Dymock¹, Anders Poulsen¹, Ramesh Jayaraman¹, Stephanie Blanchard¹, Angeline Lee¹, Haishan Wang¹, Di Zhong Chen¹, Chang Kai Soh¹. ¹S*BIO Pte Ltd, Singapore, Singapore, ²Lilly Singapore Centre for Drug Discovery, Singapore, Singapore.
• A potent and oral PI3K/mTOR inhibitor P6915 with antiangiogenic activity. Veena R. Agarwal, Geetanjali Chimote, Jayshree Srinivasan, Julie Bose, Lakshmi Sireesha Kolla, Somesh Sharma, Sanjay Kumar, Rajiv Sharma, Nikesh Desai, Asavari Joshi, Sarika Choudhari, Magesh Venkatraman, Vijaykumar Deore, Nilambari Yewalkar. Piramal Life Sciences Limited, Mumbai, Maharashthra, India.
• A survey of PTEN deficiency across different malignancies by automated immunohistochemistry. Zaina Sangale¹, Cynthia Prass¹, Amy Carlson¹, Eliso Tikishvili¹, Russell Broaddus², Bojana Djordjevic³, Steven Stone¹. ¹Myriad Genetics, Inc, Salt Lake City, UT, ²University of Texas MD Anderson Cancer Center, Houston, TX, ³University of Ottawa, Ottawa, ON, Canada.
• Akt is an important mediator for the function of DNA-PK in DNA damage repair and post-irradiation survival. Mahmoud Toulany¹, David J. Chen², H. Peter Rodemann¹. ¹University of Tuebingen, Tuebingen, Germany, ²University of Texas Southwestern Medical Center, Dallas, TX.
• Akt phosphorylation at S404 regulates prelamin A through 14.3.3 binding and degradation. Jessika Bertacchini¹, Francesca Beretti¹, Vittoria Cenni², Marianna Guida¹, Oriano Marin³, Giovanna Lattanzi², Sandra Marmiroli¹. ¹Department of Anatomy and Histology, Modena, Italy, ²IGM-CNR, Bologna, Italy, ³Department of Biological Chemistry, Padova, Italy.
• Akt regulation by ubiquitin-proteasome pathways. Futoshi Suizu, Masayuki Noguchi. Hokkaido University, Sapporo, Hokkaido, Japan.
• Akt, hypoxia and Warburg effect in primary effusion lymphoma: Potential for anticancer therapy. Federica Gibellini, Sandra Marmiroli. Università di Modena e Reggio Emilia, Modena, Italy.
• Akt/mTOR pathway analysis using MILLIPLEX® MAP Akt/mTOR phospho panel. Joseph Hwang, Wen-Rong Lie, Rick Wiese, David Hayes. Millipore Corp., Billerica, MA.
• AKT2 is dominantly activated during feedback activation after mTOR inhibition: Rationale for dual targeting of mTOR/AKT2 for the treatment of cholangiocarcinoma. Katharina Staufer, Nicole Grabinski, Bianca Hofmann, Bjoern Nashan, Manfred Juecke. University Medical Centre Hamburg Eppendorf, Hamburg, Germany.
• Aminopyrazine substituted purines as potent and selective mTOR inhibitors. Meredith Williams, Amalini Jesuthasan, Yong Cheng Tan, Bee Kheng Ng, Khalid Pasha Mohammed, Kantharaj Ethirajulu, Jeanette Wood, Brian Dymock, Stefan Hart, Harish Nagaraj, Anders Poulsen, Kee Chuan Goh, Ramesh Jayaraman, Chang Kai Soh, Veronica Diermayr, Yung Kiang Loh. S*BIO Pte Ltd, Singapore, Singapore.
• AMPK modulation and activity in chronic myeloid leukemia cells. Eliza Vakana, Leonidas C. Platanias. Northwestern University, Chicago, IL.
• ATP-competitive mTOR kinase inhibitor AZD8055 enhances immunotherapeutic activity of an agonist CD40 antibody. Qun Jiang¹, Jonathan M. Weiss¹, Timothy Back¹, Tim Chan¹, John Ortaldo¹, Sylvie Guichard², Robert H. Wiltrout¹. ¹NCI-Frederick, Frederick, MD, ²AstraZeneca, Macclesfield, United Kingdom.
• Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. Olga K. Mirzoeva¹, Byron Hann¹, Yun K. Hom¹, Jayanta Debnath¹, Dana Aftab², Kevan Shokat¹, W. Michael Korn¹. ¹University of California, San Francisco, CA, ²Exelixis, Inc., South San Francisco, CA.
• Catalytic but not allosteric inhibition of mTOR radiosensitizes inflammatory breast cancer tumors in an animal model. Eileen P. Connolly, Debborah Silvera, Toni A. Venuto, Silvia C. Formenti, Robert J. Schneider. NYU School of Medicine, New York, NY.
• Chemoresistance of pancreatic cancer may be reversed by blocking the prosurvival AKT/P13K/mTOR and mutant KRAS signaling pathways. Harold J. Wanebo¹, Shan Lu², Cong Cao², David Shrayer¹, Yinsheng Wan³, Wayne Bowen². ¹Landmark Medical Center, Woonsocket, RI, ²Brown University, Providence, RI, ³Providence College, Providence, RI.
• Class II PI 3-kinase C2β regulation by Src-mediated activation. Anna Borgström¹, Danielle Boller², Kathrin Doepfner², Alexandre Arcaro¹. ¹University of Bern, Bern, Switzerland, ²University Children's Hospital of Zurich, Zurich, Switzerland.
• Co-activation of AKT and Ras promotes rapid hepatic carcinogenesis by upregulation of mTORC1/rpS6 pathway. Chunmei Wang¹, Coral Ho¹, Susie Lee¹, Matthias Evert², Frank Dombrowski², Diego F. Calvisi², Xin Chen¹. ¹University of California, San Francisco, CA, ²University of Greifswald, Greifswald, Germany.
• Combined targeting of HER2 and mTOR as a strategy to counteract resistance to lapatinib in HER2 overexpressing breast cancers. Sherry A. Weppler, Guido J.J. Kierkels, Wieslawa H. Dragowska, Karen Gelmon, Marcel B. Bally. British Columbia Cancer Agency, Vancouver, BC, Canada.
• Combined therapeutics abrogate TSC2-null tumor growth and prevent tumor recurrence. Elena A. Goncharova, Dmitry A. Goncharov, Irene Khavin, Vera P. Krymskaya. University of Pennsylvania, Philadelphia, PA.
• Discovery of a novel series of mTOR selective inhibitors. Theodore O. Johnson¹, Simon Bailey¹, Tin Tran¹, Anle Yang¹, Michael J. Bennett¹, Mingying He¹, Jacqui E. Hoffman¹, Ted W. Johnson¹, Chunze Li¹, Matthew A. Marx², Genevieve Paderes³, Graham L. Smith¹. ¹Pfizer, San Diego, CA, ²Takeda, San Diego, CA, 3Pfizer, Groton, CT.
• Disrupting PH-kinase domain interactions leads to Akt activation. Chaitali Parikh, Subhra Chaudhuri, Nicholas Skelton, Somasekar Seshagiri. Genentech, Inc, South San Francisco, CA.
• Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma. Joseph A. Knowles¹, Li Yan², Eben L. Rosenthal¹. ¹University of Alabama, Birmingham, AL, ²Merck Research Laboratories, North Wales, PA.
• Distinct effects of S6K homologs on breast cancer cell survival. Savitha Sridharan, Alakananda Basu. University of North Texas Health Science Center and Institute for Cancer Research, Fort Worth, TX.
• Dual targeting of the PI3K-AKT-MTOR axis in HNSCC: Roadblocks due to paradoxical activation of survival kinases. Shalmali Avinash Pradhan¹, Nagashri M. N², Gopinath K. S², Arun Kumar¹. ¹Indian Institute of Science, Bangalore, Karnataka, India, ²Bangalore Institute of Oncology, Bangalore, Karnataka, India.
• Elucidating the role of PI3’-kinase pathway activation in melanoma progression in vivo. Victoria Marsh¹, Wayne Phillips², Martin McMahon¹. ¹University of California, San Francisco, CA, ²Peter MacCallum Cancer Center, Melbourne, Australia.
• Expression of the PI3-kinase mutation Pik3caH1047R in the mouse mammary gland induces ductal hyperplasia and tumorigenesis. Anjali Tikoo, Karen Montgomery, Ivan Ivetac, Vincent Roh, Anita Sridhar, Patrick Humbert, Wayne A. Phillips. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
• Feedback loop activation of Akt is not a marker of rapamycin resistance. Argun Akcakanat, Farrell Adkins, Huiqin Chen, Kim-Anh Do, Ana Maria Gonzalez-Angulo, Doris Rieko Siwak, Gopal Singh, Gordon Mills, Funda Meric-Bernstam. University of Texas MD Anderson Cancer Center, Houston, TX.
• Genetic and preclinical interrogation of a genetically engineered mouse model of small cell lung carcinoma. Patricia Hamilton, Li Li, William Forrest, Suzana Couto, Leisa Johnson, Jason Long, Anthony Lima, Rafael Molina, Tim Cao, Michelle Nannini, Richard Carano, Sankar Mohan, Ajay Pandita. Genentech, South San Francisco, CA.
• Hyperactivation of 4E-binding protein 1 by antidiabetic biguanide as its antitumor mechanisms of action. Yoshinori Tsukumo¹, Junichi Matsuo¹, Satomi Tsukahara¹, Junko Sakurai¹, Toshiki Watanabe², Shigeo Sato¹, Hiromichi Kondo³, Akihiro Tomida¹. ¹Cancer Chemotherapy Center, JFCR, Tokyo, Japan, ²The University of Tokyo, Tokyo, Japan, ³Cancer Chemotherapy Center, JFCR and ALOKA CO., LTD, Tokyo, Japan.
• Identification of autophagy proteins as biomarkers for Akt-targeted therapeutics in squamous cell carcinoma of the head and neck (SCCHN). Wen-Liang Kuo, Jing Liu, Omar Ahmed, Ezra EW Cohen. University of Chicago, Chicago, IL.
• Igf2 supply modifies development, survival, and tumorigenesis in Pten+/- mice. David N. Church¹, Ben Phillips², Daniel Stuckey¹, Emma Carter¹, Sanjiv Manek², Kieran Clarke¹, Bass Hassan¹. ¹University of Oxford, Oxford, United Kingdom, ²Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom.
• IKK-dependent phosphorylation and feedback inhibition of PI3K promotes nutrient deprivation-induced autophagy. William C. Comb¹, Jessica E. Hutti¹, Lewis C. Cantley², Albert S. Baldwin¹. ¹University of North Carolina, Chapel Hill, NC, ²Harvard Medical School, Boston, MA.
• Inhibition of PI3K sensitizes T-ALL cells to chemotherapy. André Bortolini Silveira¹, Paulo Leal², Bruno A. Cardoso³, Bárbara Nogueira¹, Rosendo A. Yunes², Silvia Regina Brandalise¹, Nilson Ivo Tonin Zanchin⁴, João Taborda Barata³, José Andrés Yunes¹. ¹Boldrini Children's Hospital, Campinas, SP, Brazil, ²Santa Catarina Federal University, Florianópolis, SC, Brazil, ³University of Lisbon, Lisbon, Portugal, ⁴The Brazilian Synchrotron Light Laboratory, Campinas, SP, Brazil.
• INK1117, a potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer. Linda Kessler¹, Katti Jessen¹, Josh Stewart¹, Levan Darjania¹, Liansheng Li¹, Katrina Chan¹, Mike Martin¹, Pingda Ren¹, David Fruman², Christian Rommel¹, Yi Liu¹, Jeff Kucharski¹, Xin Guo¹, Jocelyn Staunton¹, Marikka Elia¹, Urmi Banerjee¹, Matthew Janes¹, Lucy Lan¹, Shunyou Wang¹. ¹Intellikine, La Jolla, CA, ²UCI, Irvine, CA.
• INK128, A TORC1/2 kinase inhibitor demonstrates oral antitumor activity in preclinical models of endometrial and breast cancers and enhances efficacy of taxol. Katti Jessen, Josh Stewart, Levan Darjania, Liansheng Li, Katrina Chan, Mike Martin, Pingda Ren, Christian Rommel, Linda Kessler, Yi Liu, Marikka Elia, Jeff Kucharski, Xin Guo, Jocelyn Staunton, Urmi Banerjee, Lucy Lan, Shunyou Wang. Intellikine, La Jolla, CA.
• Investigating class IA phosphoinositide 3-kinase isoforms in glioblastoma. Katrin Höland¹, Danielle Boller², Karl Frei³, Alexandre Arcaro¹. ¹University of Bern, Bern, Switzerland, ²University Children's Hospital Zurich, Zurich, Switzerland, ³University Hospital Zurich, Zurich, Switzerland.
• Loss of TSC2 confers resistance to sphingolipid-induced death through effects on nutrient transporter expression. Garret G. Guenther, Susan Y. Wong, Aimee L. Edinger. University of California, Irvine, CA.
• MAP4K3 is a component of the TORC1 signaling complex that modulates cell growth and viability in Drosophila melanogaster. Martín D. Resnik-Docampo and Jose F. de Celis. Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid and CSIC, Madrid, Spain.
• MCT-1 oncoprotein interacts with p190RhoGAP and deregulates cytokinesis in the PTEN deficient circumstance. Meng-Hsun Wu, Li-Wei Lien, Hung-Ju Shih, Hsin-Ling Hsu. National Health Research Institutes, Zhunan, Miaoli Co., Taiwan.
• Mechanism of phosphoinositide 3-kinase C2β-dependent RhoGTPases activation in cytoskeletal organization and cell migration. Karolina Blajecka¹, Marin Marinov², Alexandre Arcaro¹. ¹University of Bern, Bern, Switzerland, ²University Children's Hospital, Zürich, Switzerland.
• mTORC1 is an important downstream mediator of WNT signaling activation in the intestinal epithelium. William J. Faller¹, Sorina M. Radulescu¹, Rachel A. Ridgway¹, Julia B. Cordero¹, Michael N. Hall², Owen J. Sansom¹. ¹Beatson Institute for Cancer Research, Glasgow, United Kingdom, ²Biozentrum, Basel, Switzerland.
• Novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) inhibits the PI3K signaling pathway and proliferation of cancer cells. Hyunseung Lee¹, Guang-Young Li¹, Hong-Mei Zheng¹, Kyung Hee Jung¹, Sang-Won Hong¹, Byung-Hee Park¹, Mi-Kwon Son¹, Sungwoo Hong², Soon-Sun Hong¹. ¹Inha University, Incheon, Republic of Korea, ²Korea Advanced Institute of Science and Technology (KAIST), Daejon, Republic of Korea.
• NVP-BEZ235 a dual PI3K/mTOR inhibitor is synthetically lethal for the MYCN-expressing childhood cancer neuroblastoma in the absence of defined PI3K pathway mutations. Lynsey Sian Vaughan¹, Karen Barker¹, Elizabeth Cullis¹, Yann Jamin¹, Simon Robinson¹, Sauveur-Michel Maira², Louis Chesler¹. ¹Institute of Cancer Research, Sutton, Surrey, England, ²Novartis Pharma AG, Basel, Switzerland.
• p37delta, a novel isoform of PI3K p110delta without catalytic domain, increases cell proliferation in vitro and in vivo. Susanne M. Fransson, Helena Eriksson, Anne Uv, Martin Bergo, Katarina Ejeskar. University of Gothenburg, Gothenburg, Sweden.
• PHLPP phosphatase regulation of growth factor receptor signaling. Matt J. Niederst, Gloria Reyes, Maya Kunkel, Jorrit Enserink, Alexandra C. Newton. University of California, San Diego, La Jolla, CA.
• PI3Kγ mediates Kaposi’s sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Daniel Martin¹, Rebeca Galisteo¹, Reinhard Wetzker², Emilio Hirsch³, J. Silvio Gutkind¹. ¹National Institute of Dental and Craniofacial Research, Bethesda, MD, ²Jena University Hospital, University Jena, Jena, Germany, ³University of Torino, Torino, Italy.
• Potent and selective PI3K inhibitors with oral antitumor activity. Kevin K.-C Liu, Genevieve Paderes, Min-Jean Yin, anle yang, Shaoxian Sun, Shubha Bagrodia, Kris Rafidi, Jerry Hu, Chunze Li, Aihua Zou, Simon Bailey, JinJiang Zhu, Graham Smith, Matthew Marx, Hengmiao Cheng, Ted O. Johnson, Jacqui Hoffman, Zhengyu Liu. Pfizer Inc, La Jolla, CA.
• Preclinical studies of the PI3K/mTOR dual inhibitor as a single agent and in combination in colorectal cancer cell lines. Joan Cao, Jing Yuan, Scott Garza, Nathan V. Lee, Kenneth Hook, Qin Zhang, James G. Christensen, Julie L.C. Kan. Pfizer, La Jolla, CA.
• Proliferation in response to the PI3K/Akt pathway is suppressed by activation of p57Kip2. Devin T. Worster¹, John G. Albeck¹, Nicole L. Solimini¹, Tobias Schmelzle², Joan S. Brugge¹. ¹Harvard Medical School, Boston, MA, ²Novartis Institutes, Basel, Switzerland.
• Role of PTEN status on MK2206 sensitivity in breast cancer. Takafumi Sangai, Argun Akcakanat, Farrell Adkins, Priscilla McAuliffe, Gordon Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam. University of Texas MD Anderson Cancer Center, Houston, TX.
• SAR development for the tricyclic imidazo[1,5]naphthyridine series: PI3K/mTOR dual inhibitor versus PI3K selective inhibitor originated from small structural changes of the inhibitors. Hengmiao Cheng, Simon Bailey, Kevin Liu, Zhengyu Liu, Matthew A. Marx, Maelena Walls, Peter A. Wells, Anle Yang, Min-Jean Yin, Peter Zhu, Sangita M. Baxi, Lance Goulet, Lisa Guo, Jacqui Hoffman, Ted O. Johnson, Ted W. Johnson, Chunze Li, John Li. Pfizer Worldwide Research & Development, San Diego, CA.
• Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Camilla Evangelisti¹, Francesca Ricci², Pierluigi Tazzari², Francesca Chiarini¹, Andrea Pession³, James McCubrey⁴, Alberto Maria Martelli¹. ¹Dept.of Human Anatomical Sci., University of Bologna, Bologna, Italy, ²Transfusion Center, Policlinico S.Orsola-Malpighi, Bologna, Italy, ³Pediatric Hematology and Oncology Unit, University of Bologna, Bologna, Italy, ⁴East Carolina University School of Medicine, Grenville, NC.
• Targeting phosphoinositide 3-kinases as a new potential therapeutic strategy for the treatment of medulloblastoma. Fabiana Salm¹, Ana Guerreiro², Barbara Fischer², Alexandre Arcaro¹. ¹University of Bern, Bern, Switzerland, ²University Children's Hospital Zurich, Zurich, Switzerland.
• Targeting Rb mutant cancers by inactivating TSC2. Wei Du, Binghui Li. University of Chicago, Chicago, IL.
• Targeting the cotranslational function of mTOR complex 2 for cancer therapy. Won Jun Oh¹, Chang-chih Wu¹, Po-chien Chou¹, Sung Jin Kim¹, Guy Werlen², Estela Jacinto¹. ¹UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ, ²Rutgers The State University of New Jersey, Piscataway, NJ.
• Targeting the PTEN/Akt/mTOR pathway in human prostate cancer. Dominika Butler¹, Anne Collins¹, Barry Davies², Norman Maitland¹. ¹University of York, York, United Kingdom, ²AstraZeneca UK Limited, Macclesfield, Cheshire, United Kingdom.
• Temsirolimus increases free raptor but not free rictor in two human neuroblastoma cell lines. Don Coulter¹, Shannon O. Huennekens², Billie M. Moats-Staats². ¹University of Nebraska Medical Center, Omaha, NE, ²University of North Carolina, Chapel Hill, NC.
• The active-site TOR inhibitor INK128 blocks proliferation and survival of leukemia and lymphoma cells. David A. Fruman¹, Matthew R. Janes², Collin Vu¹, Marie P. Shieh¹, Paul Willett¹, Yi Liu², Christian Rommel². ¹University of California, Irvine, CA, ²Intellikine, Inc., La Jolla, CA.
• The chemistry and biology of mTOR selective inhibitors. Ted W. Johnson, Simon Bailey, Tod Smeal, Marlena Walls, Peter A. Wells, Min-Jean Yin, Minerva Batugo, Nathan V. Lee, Alexei Brooun, Pramod P. Mehta, Bernadette Pascual, Sangita Baxi, Kevin Bunker, Dac M. Dinh, Mingying He, Jacqui E. Hoffman, Julie Kan, Hieu Lam, Paul F. Richardson. Pfizer, San Diego, CA.
• The effects of rapamycin treatment on MSI-high intestinal cancers. KyeRyoung Lee, Hiroshi Koga, Ana Maria Cuervo, Winfried Edelmann. Albert Einstein College of Medicine, Bronx, NY.
• The gliomasphere as a platform for exploring novel therapies targeting the PI3-kinase pathway. James Dimou¹, Giovanna M. D'Abaco¹, Antony W. Burgess², Lucy Paradiso¹, Katharine J. Drummond¹, Andrew H. Kaye¹, Andrew P. Morokoff¹. ¹University of Melbourne, Parkville, VIC, Australia, ²Ludwig Institute for Cancer Research, Parkville, VIC, Australia.
• The miRNA-17~92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Enyu Rao¹, Wing Chan¹, Kai Fu¹, Chunsun Jiang¹, Ming Ji¹, Javeed Iqbal¹, Geroge Lenz², George Wright², Louis M. Staudt², Yong Zhao³, Timothy McKeithan¹. ¹University of Nebraska Medical Center, Omaha, NE, ²National Cancer Institute, Bethesda, MD, ³Chinese Academy of Sciences, Beijing, China.
• The Pik3ca mouse: A novel mouse model for studying Pik3caH1047R induced tumorigenesis. Karen Montgomery¹, Wayne A. Phillips¹, Lauren Hare¹, Anjali Tikoo¹, Kathryn Kinross¹, Ivan Ivetac¹, Vincent Roh¹, Matthias Ernst², Robert G. Ramsay¹, Patrick Humbert¹. ¹Peter MacCallum Cancer Centre, Melbourne, VIC, Australia, ²Ludwig Institute for Cancer Research, Melbourne, VIC, Australia.
• The regulation of the transcription factor SREBP by the Akt/mTORC1 pathway and hypoxia. Caroline A. Lewis¹, Karim Bensaad², Beatrice Griffiths¹, Mario Pende³, Adrian L. Harris², Almut Schulze¹. ¹CRUK London Research Institute, London, United Kingdom, ²CRUK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Oxford, United Kingdom, ³INSERM, U845; Université Paris Descartes, Paris, France.
• Tissue-specific transcriptional activation of PTEN by GRHL3 is critical for prevention of skin cancer. Charbel Darido¹, Smitha Georgy¹, Tomasz Wilanowski², Richard B. Pearson³, Stephen M. Jane⁴. ¹Royal Melbourne Hospital, Melbourne, VIC, Australia, ²Nencki Institute, Warsaw, Poland, ³Peter MacCallum Cancer Centre, Melbourne, VIC, Australia, ⁴University of Melbourne, Melbourne, VIC, Australia.
• α-TEA plus tamoxifen combination circumvents tamoxifen resistance via disruption of cholesterol-rich microdomains, suppression of prosurvival mediators and activation of endoplasmic reticulum stress. Weiping Yu, Richa Tiwary, Bob G. Sanders, Kimberly Kline. University of Texas, Austin, TX.